Gilead and Precision Biosciences Collaborates to Develop and Commercialize therapies for the Treatment of HBV using ARCUS Technology
Shots:
- Gilead will be paying Precision $445M as a milestone payment at specific development stages in addition to the double digit royalties (<19%) from sales
- Under the agreement- Precision will manage development- formulation & preclinical evaluation of nucleases whereas- Gilead will do clinical development & commercialization of therapies
- The cccDNA (covalently closed circular DNA) allows HBV replication as the presently used treatment doesn’t remove the virus completely while the ARCUS will eliminate HBV cccDNA in vitro form the body
- Currently ~257M people are affected with HBV infection- these therapies will help in advancing the treatment for HBV using Precision’s proprietary genome editing platform ARCUS technology
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
